Selective Chemistry Enables Simultaneous ImmunoPET and Radioimmunotherapy with a Dual-Labeled Probe

• Characterizing RLT-induced immune modulation and its role in tumor sensitization and resistance
• Evaluating preclinical combinations of RLT with immune checkpoint inhibitors, CAR-T cells, and emerging immunotherapies
• Leveraging synergistic immune– radiobiological mechanisms to enhance depth and durability of response

Speakers:

Brian Zeglis

Associate Professor

Hunter College of City University